Sunitinib in pancreatic neuroendocrine tumors. Clinical case
https://doi.org/10.21518/2079-701X-2019-19-114-118
Abstract
The article describes a rare clinical case. Progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal region was detected in a 33-year-old patient with G2 pancreatic neuroendocrine tumour (NET) 1.5 months after surgical treatment. The patient received targeted therapy with sunitinib, oral protein kinase inhibitor, at daily dose of 37.5 mg and biotherapy with lanreotide, an analogue of somatostatin, which is used as a monthly subcutaneous injection. A partial effect in the form of reduction of all previously identified metastatic foci was reported after 12 months of treatment. Magnetic resonance imaging (MRI) showed a full therapeutic effect after 17 months of co-use of two drugs. So far, the patient continues to receive treatment for 25 months. Complete resolution of metastatic lesions persists for 8 months. The article shows the possibility of increasing anti-tumour efficacy in using targeted therapy combined with somatostatin analogues. The combined use of sunitinib and lanreotide has a pronounced anti-tumour effect in the first line therapy for highly differentiated pancreatic NEO and is tolerated without significant toxicity. With long-term treatment, the ease of use and availability of the required dosage of Sunitinib-Nativ oral preparation and ready-to-use injection depot makes it possible to maintain a regular lifestyle, professional activity and do not affect significantly the patients’ quality of life. It is necessary to continue the study of this first-line therapy regimen for pancreatic NET under clinical protocols.
About the Authors
A. A. Markovich
Federal State Budgetary Institution «N.N.Blokhin National Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Senior Researcher, Scientific Advisory Department of Outpatient Diagnostic and Treatment Methods
24 Kashirskoe shosse, Moscow, 115478, Russia
A. A. Kuznetsova
Federal State Budgetary Institution «N.N.Blokhin National Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Oncologist, Scientific Advisory Department of Outpatient Diagnostic and Treatment Methods
24 Kashirskoe shosse, Moscow, 115478, Russia
E. L. Dronova
Federal State Budgetary Institution «N.N.Blokhin National Cancer Research Center» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Radiologist, Radiology Department, Research Institute of Clinical and Experimental Radiology
24 Kashirskoe shosse, Moscow, 115478, Russia
G. S. Emel’yanova
Federal State Budgetary Educational Institution of Higher Education «A.I.Yevdokimov Moscow State University of Medicine and Dentistry» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Teaching Assistant, Chair for Oncology
Bldg.1, 20, Delegatskaya St., Moscow, 1127473, Russia
References
1. Fjallskog M.L., Lejonklou M.H., Oberg K.E., Eriksson B.K., Janson E.T. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res. 2003;9(4):1469–1473. Available at: https://clincancerres.aacrjournals.org/content/9/4/1469.long.
2. Kulke M.H., Lenz H.J., Meropol N.J., Posei J., Ryan D.P., Picus J., Bergsland E., Stuart K., Tye L., Huang X., Li J.Z., Baum C.M., Fuchs C.S. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26(20):3403–3410. doi: 10.1200/JCO.2007.15.9020.
3. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., Lombard-Bohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J.S., Hörsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D.R., Blanckmeister C., Chao R., Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501–513. doi: 10.1056/NEJMoa1003825.
4. Valle J.W., Borbath I., Rosbrook B., Fernandez K., Raymond E. Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. Future Oncology. 2019;15(11):1219-1230. doi: 10.2217/fon-2018-0882.
5. Faivre S., Niccoli P., Castellano D., Valle J.W., Hammel P., Raoul J.L., Vinik A., Van Cutsem E., Bang Y.J., Lee S.H., Borbath I., Lombard-Bohas C., Metrakos P., Smith D., Chen J.S., Ruszniewski P., Seitz J.F., Patyna S., Lu D.R., Ishak K.J., Raymond E. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a Phase III randomized study. Ann Oncol. 2016;28(2):339–343. doi: 10.1093/annonc/mdw561.
6. Raymond E., Kulke M.H., Qin S., Yu X., Schenker M., Cubillo A., Lou W., Tomasek J., Thiis-Evensen E., Xu J.M., Croitoru A.E., Khasraw M., Sedlackova E., Borbath I., Ruff P., Oberstein P.E., Ito T., Jia L., Hammel P., Shen L., Shrikhande S.V., Shen Y.,
7. Sufliarsky J., Khan G.N., Morizane C., Galdy S., Khosravan R., Fernandez K.C., Rosbrook B., Fazio N. Efficacy and safety of sunitinib in patients with well-differentiated pancreatic neuroendocrine tumours. Neuroendocrinology. 2018;107(3):237–245. doi: 10.1159/000491999.
8. Rinzivillo M., Fazio N., Pusceddu S., Spallanzani A., Ibrahim T., Campana D., Marconcini R., Partelli S., Badalamenti G., Brizzi M.P., Catena L., Schinzari G., Carnaghi C., Berardi R., Faggiano A., Antonuzzo L., Spada F., Gritti S., Femia D., Gelsomino F., Bongiovanni A., Ricci S., Brighi N., Falconi M., Delle Fave G., Panzuto F. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: a real-world study. Pancreatology. 2018;18(2):198–203. doi: 10.1016/j.pan.2018.01.005.
9. Theodoropoulou M., Stalla G.K. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013;34(3):228–252. doi: 10.1016/j.yfrne.2013.07.005.
10. Kulaksiz H., Eissele R., Rössler D., Schulz S., Höllt V., Cetin Y., Arnold R.. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50(1):52–60. doi: 10.1136/gut.50.1.52.
11. Somvanshi R.K., Kumar U. Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin Receptors. Pharmaceuticals (Basel). 2012;5(5):417–446. doi: 10.3390/ph5050417.
12. Modlin I.M., Pavel M., Kidd M., Gustafsson B.I. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther. 2010;31(2):169–188. doi: 10.1111/j.1365-2036.2009.04174.x.
13. Wilson B.J., Harada R., LeDuy L., Hollenberg M.D., Nepveu A. CUX1 transcription factor is a downstream effector of the proteinase-activated receptor 2 (PAR2). J Biol Chem. 2009;284(1):36–45. doi: 10.1074/jbc.M803808200.
14. Segal N.H., Saltz L.B. Evolving treatment of advanced colon cancer. Annu Rev Med. 2009;(60):207–219. doi: 10.1146/annurev.med.60.041807.132435.
15. Yao J.C., Lombard-Bohas C., Baudin E., Kvols L.K., Rougier P., Ruszniewski P., Hoosen S., St Peter J., Haas T., Lebwohl D., Van Cutsem E., Kulke M.H., Hobday T.J., O’Dorisio T.M., Shah M.H., Cadiot G., Luppi G., Posey J.A., Wiedenmann B. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28(1):69–76. doi: 10.1200/JCO.2009.24.2669.
16. Bajetta E., Catena L., Pusceddu S., Spada F., Iannacone C., Sarno I., Di Menna G., Dottorini L., Marte A.M. Everolimus in Combination with Octreotide Long-Acting Repeatable in a FirstLine Setting for Patients with Neuroendocrine Tumors: A 5-Year Update. Neuroendocrinology. 2018;106(4):307–311. doi: 10.1159/000479587.
17. Krug S., Mordhorst J.P., Moser F., Theuerkorn K., Ruffert C., Egidi M., Rinke A., Gress T.M., Michl P. Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells. PLoS One. 2019;14(6):e0218953. doi: 10.1371/journal.pone.0218953.
18. Durán-Prado M., Saveanu A., Luque R.M., Gahete M.D., Gracia-Navarro F., Jaquet P., Dufour H., Malagón M.M., Culler M.D., Barlier A., Castaño J.P. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab. 2010;95(5):2497-2502. doi: 10.1210/jc.2009-2247.
19. Caplin M.E., Pavel M., Ćwikła J.B., Phan A.T., Raderer M., Sedláčková E., Cadiot G., Wolin E.M., Capdevila J., Wall L., Rindi G., Langley A., Martinez S., Gomez-Panzani E., Ruszniewski P. CLARINET Investigators. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016;23(3):191-199. doi: 10.1530/ERC-15-0490
20. Capdevila J., Sevilla I., Alonso V., Antón Aparicio L., Jiménez Fonseca P., Grande E., Reina J.J., Manzano J.L., Alonso Lájara J.D., Barriuso J., Castellano D., Medina J., López C., Segura Á., Carrera S., Crespo G., Fuster J., Munarriz J., García Alfonso P. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015;(15):495. doi: 10.1186/s12885-015-1512-6.
Review
For citations:
Markovich AA, Kuznetsova AA, Dronova EL, Emel’yanova GS. Sunitinib in pancreatic neuroendocrine tumors. Clinical case. Meditsinskiy sovet = Medical Council. 2019;(19):114-118. (In Russ.) https://doi.org/10.21518/2079-701X-2019-19-114-118
Views:
725
Email this article 